According to FutureWise analysis the market for alpha-1 antitrypsin deficiency augmentation therapy is expected to reach US$ 2.63 billion by 2031 at a CAGR of 6.10%. Alpha-1 Antitrypsin Deficiency (AATD) is a challenging genetic disorder that can lead to serious lung and liver issues. Thankfully, there's hope with augmentation therapy, a long-term treatment designed specifically for those...